Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-03-23

Clinical Trial Update: The Effects of LAF237 on Gastric Function in Type 2 Diabetes [Phase 3]

View source ↗

Summary

A completed Phase 3 clinical trial evaluated the effects of LAF237 on gastric function in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAF237 (linagliptin) (linagliptin)

Snippet

Sponsor: Mayo Clinic | Conditions: Diabetes Mellitus, Non-Insulin-Dependent | Phase 3 | Status: COMPLETED